206 related articles for article (PubMed ID: 24782116)
21. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
23. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
24. The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist.
Preston RA; Marbury TC; Wajima T; Graham S
Am J Ther; 2015; 22(3):171-81. PubMed ID: 24413373
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.
Stroh M; Wenning L; Luo WL; Desai R; Bi S; Keshavarz S; Lazarus N; Lunde NM; Smith WB; Schwartz M; Stone J; Wagner J; Lai E; Dishy V
Am J Ther; 2009; 16(5):379-84. PubMed ID: 19433974
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
Krishna R; Gheyas F; Corr C; Cote J; Liu Y; Wagner J; Gutstein DE
J Clin Pharmacol; 2018 Dec; 58(12):1578-1585. PubMed ID: 30029292
[TBL] [Abstract][Full Text] [Related]
27. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment.
Li Z; Gan LS; Marbury T; Lasseter KC; Natarajan A; Stecher S; Wei D; Yang L; Freedman D; Deykin A
J Clin Pharmacol; 2012 Apr; 52(4):543-51. PubMed ID: 21610206
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
Kunz C; Luedtke D; Unseld A; Hamilton A; Halabi A; Wein M; Formella S
Int J Chron Obstruct Pulmon Dis; 2016; 11():585-95. PubMed ID: 27051282
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
[TBL] [Abstract][Full Text] [Related]
32. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
33. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
34. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
Borghi C; Cicero AF
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):205-209. PubMed ID: 27852117
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
37. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
[TBL] [Abstract][Full Text] [Related]
39. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
